MX2018008339A - Multimeros fc de inmunoglobulina g recombinante. - Google Patents
Multimeros fc de inmunoglobulina g recombinante.Info
- Publication number
- MX2018008339A MX2018008339A MX2018008339A MX2018008339A MX2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A
- Authority
- MX
- Mexico
- Prior art keywords
- multimers
- recombinant igg
- igg
- recombinant
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta descripción provee multimeros Fc de IgG recombinante y métodos para tratar enfermedades autoinmunes e inflamatorias mediante la administración de dichos multímeros.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16152867 | 2016-01-27 | ||
EP16162166 | 2016-03-24 | ||
EP16195116 | 2016-10-21 | ||
PCT/EP2017/051757 WO2017129737A1 (en) | 2016-01-27 | 2017-01-27 | Recombinant igg fc multimers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018008339A true MX2018008339A (es) | 2018-09-17 |
Family
ID=57956274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008339A MX2018008339A (es) | 2016-01-27 | 2017-01-27 | Multimeros fc de inmunoglobulina g recombinante. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190119377A1 (es) |
EP (1) | EP3408279A1 (es) |
JP (1) | JP2019511458A (es) |
KR (1) | KR20180100701A (es) |
CN (1) | CN108602857A (es) |
AU (1) | AU2017213117A1 (es) |
BR (1) | BR112018014668A2 (es) |
CA (1) | CA3012037A1 (es) |
HK (1) | HK1258166A1 (es) |
MX (1) | MX2018008339A (es) |
RU (1) | RU2018130525A (es) |
SG (2) | SG11201805579SA (es) |
WO (1) | WO2017129737A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116970061A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
CN112004550A (zh) * | 2017-12-14 | 2020-11-27 | 康诺贝林伦瑙有限公司 | 用于治疗视神经脊髓炎的重组IgG Fc多聚体 |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
EP3775926A1 (en) | 2018-08-30 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
BR112021011107A2 (pt) | 2018-12-13 | 2021-12-14 | Argenx Bvba | Anticorpos para o fator de complemento humano c2b e métodos de uso |
KR20220062084A (ko) * | 2019-09-13 | 2022-05-13 | 체에스엘 베링 렝나우 아게 | 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 |
KR20220066075A (ko) * | 2019-09-20 | 2022-05-23 | 큐 바이오파마, 인크. | T-세포 조절 폴리펩타이드 및 이의 사용 방법 |
CA3153207A1 (en) * | 2019-10-16 | 2021-04-22 | Chugai Seiyaku Kabushiki Kaisha | An antibody, a pharmaceutical composition, and a method |
MX2022006703A (es) | 2019-12-06 | 2022-07-12 | CSL Behring Lengnau AG | Composiciones estables de multimeros fc. |
WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
CN114894911B (zh) * | 2022-03-18 | 2023-10-24 | 辽宁成大生物股份有限公司 | 一种控制牛血清产品质量方法 |
CN118027155B (zh) * | 2024-04-15 | 2024-07-16 | 中国人民解放军军事科学院军事医学研究院 | 一种tpor结合肽及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013049254A1 (en) * | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
BR112015000167B1 (pt) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
CN104870055A (zh) * | 2012-10-17 | 2015-08-26 | 利物浦热带医学院 | 免疫调节蛋白 |
US11352414B2 (en) * | 2014-03-05 | 2022-06-07 | UCB Biopharma SRL | Multimeric Fc proteins |
SG11201606596PA (en) * | 2014-03-05 | 2016-09-29 | Ucb Biopharma Sprl | Multimeric fc proteins |
-
2017
- 2017-01-27 SG SG11201805579SA patent/SG11201805579SA/en unknown
- 2017-01-27 KR KR1020187024678A patent/KR20180100701A/ko unknown
- 2017-01-27 CA CA3012037A patent/CA3012037A1/en not_active Abandoned
- 2017-01-27 BR BR112018014668-4A patent/BR112018014668A2/pt not_active IP Right Cessation
- 2017-01-27 MX MX2018008339A patent/MX2018008339A/es unknown
- 2017-01-27 JP JP2018539140A patent/JP2019511458A/ja active Pending
- 2017-01-27 WO PCT/EP2017/051757 patent/WO2017129737A1/en active Application Filing
- 2017-01-27 SG SG10201911561SA patent/SG10201911561SA/en unknown
- 2017-01-27 RU RU2018130525A patent/RU2018130525A/ru not_active Application Discontinuation
- 2017-01-27 EP EP17702590.5A patent/EP3408279A1/en not_active Withdrawn
- 2017-01-27 CN CN201780008312.9A patent/CN108602857A/zh active Pending
- 2017-01-27 AU AU2017213117A patent/AU2017213117A1/en not_active Abandoned
- 2017-01-27 US US16/072,678 patent/US20190119377A1/en not_active Abandoned
-
2019
- 2019-01-14 HK HK19100521.7A patent/HK1258166A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018130525A3 (es) | 2020-05-29 |
CN108602857A (zh) | 2018-09-28 |
EP3408279A1 (en) | 2018-12-05 |
AU2017213117A1 (en) | 2018-07-19 |
SG10201911561SA (en) | 2020-02-27 |
CA3012037A1 (en) | 2017-08-03 |
WO2017129737A1 (en) | 2017-08-03 |
JP2019511458A (ja) | 2019-04-25 |
RU2018130525A (ru) | 2020-02-27 |
KR20180100701A (ko) | 2018-09-11 |
HK1258166A1 (zh) | 2019-11-08 |
BR112018014668A2 (pt) | 2018-12-11 |
SG11201805579SA (en) | 2018-08-30 |
US20190119377A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008339A (es) | Multimeros fc de inmunoglobulina g recombinante. | |
CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
CY1121473T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1123381T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EP3506926A4 (en) | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | |
MX2018008515A (es) | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias. | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA202190903A2 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний | |
EA201992609A1 (ru) | Слитые белки, содержащие интерлейкин-2, и их применения | |
PH12017501522A1 (en) | Antibodies to tau and uses thereof | |
GEP201706794B (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
EA201691521A1 (ru) | Антитела к интерлейкину-21 | |
EA201790565A1 (ru) | Композиции и способы для лечения предраковых поражений кожи | |
MX2018002447A (es) | Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lupica. | |
MX2018007408A (es) | Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes. | |
MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: CSL BEHRING LENGNAU AG |